AUTHOR=Freeman Debra , Dickerson Gregg , Perman Mark
TITLE=Multi-Institutional Registry for Prostate Cancer Radiosurgery: A Prospective Observational Clinical Trial
JOURNAL=Frontiers in Oncology
VOLUME=4
YEAR=2015
URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2014.00369
DOI=10.3389/fonc.2014.00369
ISSN=2234-943X
ABSTRACT=Objective: To report on the design, methodology, and early outcome results of a multi-institutional registry study of prostate cancer radiosurgery.
Methods: The Registry for Prostate Cancer Radiosurgery (RPCR) was established in 2010 to further evaluate the efficacy and toxicity of prostate radiosurgery (SBRT) for the treatment of clinically localized prostate cancer. Men with prostate cancer were asked to voluntarily participate in the registry. Demographic, baseline medical, and treatment-related data were collected and stored electronically in a Health Insurance Portability and Accountability Act-compliant database, maintained by Advertek, Inc. Enrolled men were asked to complete short, multiple choice questionnaires regarding their bowel, bladder, and sexual function. Patient-reported outcome forms were collected at baseline and at regular intervals (every 3–6 months) following treatment. Serial prostate-specific antigen measurements were obtained at each visit and included in the collected data.
Results: From July 2010 to July 2013, nearly 2000 men from 45 participating sites were enrolled in the registry. The majority (86%) received radiosurgery as monotherapy. At 2 years follow-up, biochemical disease-free survival was 92%. No Grade 3 late urinary toxicity was reported. One patient developed Grade 3 gastrointestinal toxicity (rectal bleeding). Erectile function was preserved in 80% of men <70 years old. Overall compliance with data entry was 64%.
Conclusion: Stereotactic radiosurgery is an alternative option to conventional radiotherapy for the treatment of organ-confined prostate cancer. The RPCR represents the collective experience of multiple institutions, including community-based cancer centers, with outcome results in keeping with published, prospective trials of prostate SBRT.